ClinicalTrials.gg
RecruitingNCT05701059Updated Feb 13, 2026

Comparison of Artificial Disc Implants in Cervical Disc Arthroplasty

An observational study in Cervical Spondylosis With Myelopathy, Cervical Radiculopathy and Cervical Disc Herniation, sponsored by University of California, Los Angeles. Recruiting at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by University of California, Los Angeles · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 127 studies in Radiculopathy with a site in United States — 30 open to participants now, 38 under way, 2 of them phase 3. Radiculopathy · United States.

Planned enrollment
16th of 21
20 · median 58
Started
2023
with 4 others
Observational
21 of 127
6 open now
Primary completion
2026-07
later than 11 of 37 live
Registered
107th of 127
by date

Among the 127 studies in Radiculopathy with a site in United States, this one is the 16th largest by planned enrollment of the 21 observational ones that give a count, is one of 5 that started in 2023, is one of 21 observational ones, reaches primary completion later than 11 of the 37 other live ones, and was the 107th registered.

Radiculopathy

488 studies on the registry are indexed under Radiculopathy; 145 are open to participants now.

Browse Radiculopathy studies →

Open to participants now

30 of the 127 studies in Radiculopathy with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 30 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 79 Radiculopathy studies recruiting now, 23 (29%) set no upper age limit and 48 (61%) stop at 75 or younger; 3 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Radiculopathy with a site in United States, or all of them as a file.
02

Study summary

This study will comprehensively evaluate the outcomes and endpoints of these two different FDA-approved artificial disc implants used to treat cervical spondylotic myelopathy and/or radiculopathy today: Biomet Zimmer Mobi-C and Nuvasive Simplify. Both implants are structurally different with the Nuvasive Simplify implementing a three-piece design with two endplates and a semi-constrained mobile core while the Biomet Zimmer Mobi-C implements an unconstrained three piece design. Subjects will be age-matched and randomly assigned to either implant with informed consent. All subjects will undergo a variety of assessments that evaluate neck disability, quality of life, pain, physiological outcome (radiographic assessments), and neck range-of motion before and after their procedure. One baseline testing will be conducted along with three post-operation visits (three months, six months, and one year) in accordance to standard follow-up procedure. Thus, the duration of participation in the study will be approximately one and a half years.

Read the detailed description

In cases where surgery is indicated, treatment for cervical spondylotic myelopathy and/or radiculopathy (typically caused by disc herniation or degenerative disc disease) has traditionally been performed by a procedure known as anterior cervical discectomy and fusion (ACDF) to treat a damaged disc in the neck area of the spine. However, medical advancement in this field has allowed for a new procedure often referred to as cervical arthroplasty that implements artificial disc implantation. These implants mimic the function and structure of discs by cushioning the neck's vertebral bones instead of fusing them and providing flexibility for head movements. The emergence of different artificial disc implants that are structurally and mechanistically different calls for a comparative analysis that evaluates performance across a comprehensive set of patient outcomes.

This study will comprehensively evaluate the outcomes and endpoints of these two different FDA-approved artificial disc implants used to treat cervical spondylotic myelopathy and/or radiculopathy today: Biomet Zimmer Mobi-C and Nuvasive Simplify. Both implants are structurally different with the Nuvasive Simplify implementing a three-piece design with two endplates and a semi-constrained mobile core while the Biomet Zimmer Mobi-C implements an unconstrained three piece design. Subjects will be age-matched and randomly assigned to either implant with informed consent. All subjects will undergo a variety of assessments that evaluate neck disability, quality of life, pain, physiological outcome (radiographic assessments), and neck range-of motion before and after their procedure. One baseline testing will be conducted along with three post-operation visits (three months, six months, and one year) in accordance to standard follow-up procedure. Thus, the duration of participation in the study will be approximately one and a half years.

This study has significant implications in better assessing the overall efficacy of cervical arthroplasty while providing insight to the differences in outcomes based on the artificial disc implanted. Findings can also contribute to characterizing the advantages and disadvantages of both implants to aid surgeons in making more informed and personalized treatment recommendations according to the needs of the patient.

03

Conditions studied

  • Cervical Spondylosis With Myelopathy
  • Cervical Radiculopathy
  • Cervical Disc Herniation
  • Degenerative Disc Disease

Keywords

  • cervical
  • spondylosis
  • myelopathy
  • radiculopathy
  • disc
  • cervical disc
  • artificial disc
  • artificial disc implantation
  • cervical arthroplasty
  • disc herniation
  • degenerative disc disease
  • ACDF
  • Biomet Zimmer Mobi-C
  • Nuvasive Simplify
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Subjects must be experiencing cervical spondylotic myelopathy and/or radiculopathy typically caused by disc herniation or degenerative disc disease at a single level between C3 to C7 after being unresponsive to at least six weeks of non-surgical conservative care. This study is for patients who have the intention of undergoing cervical arthroplasty and have already been recommended to do so by a doctor.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is skeletally mature and between 18 to 60 years of age
  • Experiences cervical spondylotic myelopathy and/or radiculopathy typically caused by disc herniation or degenerative disc disease at a single level between C3 to C7
  • Is unresponsive to at least six weeks of non-surgical conservative care
  • Has the intention of undergoing cervical arthroplasty for their chief complaint
  • Signed form

Exclusion criteria

Exclusion Criteria:

  • Patient has had prior cervical spine surgery
  • Has more than two diseased levels requiring surgery
  • Has a known allergy to a metal alloy or polyethylene
  • Is morbidly obese
  • Has active local or system infection
  • Has any circumstances or conditions such that their ability to provide comply with follow-up requirements, or provide self-assessments is compromised (eg: psychiatric disorders, chronic alcohol or substance abuse, etc.)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20 participants (estimated)
Patient registry
No

Groups and cohorts

  • Semi-Constrained Nuvasive Simplify

    This group will be undergoing cervical arthroplasty with the Nuvasive Simplify artificial disc implant. The Nuvasive Simplify implements a three-piece design with two endplates and a semi-constrained mobile core.

    Procedure: Cervical arthroplasty · Device: Semi-Constrained Nuvasive Simplify

  • Unconstrained Biomet Zimmer Mobi-C

    This group will be undergoing cervical arthroplasty with the Biomet Zimmer Mobi-C artificial disc implant. The Biomet Zimmer Mobi-C implements an unconstrained three piece design.

    Procedure: Cervical arthroplasty · Device: Unconstrained Biomet Zimmer Mobi-C

Interventions

  • ProcedureCervical arthroplasty

    A joint replacement procedure administered by inserting an artificial disc between the vertebrae to replace a natural spinal disc after it has been removed.

    Also known as: Cervical artificial disc replacement surgery

  • DeviceSemi-Constrained Nuvasive Simplify

    This weight-bearing implant consisting of PEEK (polyetheretherketone) endplates and one semi-constrained, fully articulating, mobile zirconia toughened alumina (ZTA) ceramic core will be administered by cervical arthroplasty into the specified single-level cervical region.

  • DeviceUnconstrained Biomet Zimmer Mobi-C

    This unconstrained, three-piece implant will be administered by cervical arthroplasty into the specified single-level cervical region.

06

What researchers measure

Primary outcomes

  1. Cervical range of motion assessments with VICON

    Will measure flexion/extension, lateral bending, rotation, protraction/retraction in degrees. The outcome will reflect any improvement in physiological neck range of motion be patients undergoing this procedure.

    Time frame: Will be conducted before surgery (baseline), and 3 months, 6 months, and 1 year post-operation.

Secondary outcomes

  1. Questionnaires on neck disability

    Will administer surveys on neck disability index, work status, pain intensity worksheet, treatment satisfaction form, and the SF-12 v2 Health Survey. The 12-item Short Form Survey version 2 (SF-12 v2) is a general health questionnaire that reports two summary scores - a mental component score (MCS-12) and a physical component score (PCS-12). The scores are reported as Z-scores (difference compared to the population average, measured in standard deviations) with the US population average PCS-12 and MCS-12 being both 50 points. Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning. Overall, these assessments will help to gauge overall quality of life, pain, and patient satisfaction with their treatment.

    Time frame: Will be conducted before surgery (baseline), and 3 months, 6 months, and 1 year post-operation.

  2. Neurological examination: gait assessment

    Will take place as part of standard care for this operation. A gait assessment will be performed according to Nurick's Classification. Nurick's classification is graded from 0-5 or normal, with a number grade denoting some neurological deficit. 0 is least severe, with the patient showing root signs and symptoms with no evidence of spinal cord involvement. Grade 5 is most severe, described as chair bound or bedridden.

    Time frame: Will be conducted before surgery (baseline), and 3 months, 6 months, and 1 year post-operation.

  3. Neurological examination: foraminal compression test

    The foraminal compression test is a physical examination technique which reduces the opening of the foramen which may demonstrate if there is pressure upon the exiting spinal nerve. The test is done to detect spinal nerve root involvement, a herniated disc, bulging disc, or foraminal stenosis. The scoring is binary, either negative or positive, to test for any pain the patient experiences during the exam.

    Time frame: Will be conducted before surgery (baseline), and 3 months, 6 months, and 1 year post-operation.

  4. Radiographic assessments: disc height

    Will take place as part of standard care for this operation. Anterior and Posterior Disc Height will be measured from neutral lateral radiographs. Anterior (Posterior) Disc Height is defined as the distance between the anterior-inferior (posterior-inferior) corner of the superior vertebra, and the corresponding corner of the inferior vertebra. This distance is measured perpendicular to the superior endplate of the inferior vertebra and will be reported in units of millimeters. Average Disc Height is calculated as the simple average of the Anterior and Posterior Disc Heights.

    Time frame: Will be conducted before surgery (baseline), and 3 months, 6 months, and 1 year post-operation.

  5. Radiographic assessments: disc angle

    Disc Angle is the angle formed between the endplates of adjacent vertebrae. Disc Angle will be measured on neutral lateral radiographs to assess local segmental lordosis and will be reported in degrees.

    Time frame: Will be conducted before surgery (baseline), and 3 months, 6 months, and 1 year post-operation.

  6. Radiographic assessments: global range of motion (C2-C6)

    Global range of motion will be measured on lateral flexion-extension views to evaluate global range of motion. Global C2-C6 range of motion will be calculated by subtracting the C2-C6 angle in flexion from the C2-C6 angle in extension. Global range of motion will be measured between the inferior endplate of C2 and the inferior endplate of C6. C2-C6 Angle will be measured in units of degrees.

    Time frame: Will be conducted before surgery (baseline), and 3 months, 6 months, and 1 year post-operation.

  7. Radiographic assessments: translational motion

    Translational Motion will be calculated from flexion-extension radiographs. Translational Motion is defined as displacement of the posterior-inferior corner of the superior vertebra in a direction defined parallel to the superior endplate of the inferior vertebra. Translational Motion will be reported in units of millimeters and as a percent of the AP dimension of the superior endplate of the inferior vertebra.

    Time frame: Will be conducted before surgery (baseline), and 3 months, 6 months, and 1 year post-operation.

  8. Radiographic assessments: device subsidence

    Device Subsidence will assess significant cranial-caudal movement of the implant and will be graded in accordance with the following definitions: 0\. None: No evidence of cranial or caudal subsidence of the implant \> 3 mm. 1. Cranial: Presence of cranial movement of the device \> 3 mm relative to the initial position of the implant at PostOp. 2. Caudal: Presence of caudal movement of the device \> 3 mm relative to the initial position of the implant at PostOp. Subsidence will be evaluated relative to the first available post-operative visit. A threshold of \>3 mm of implant motion will be used to define significance. Subsidence will be assessed in the cranial and caudal directions perpendicular to the vertebral endplates and based on the degree of penetration of the implant into the bony margins of the vertebral body.

    Time frame: Will be conducted before surgery (baseline), and 3 months, 6 months, and 1 year post-operation.

  9. Radiographic assessments: Kellgren-Lawrence Assessment

    Kellgren-Lawrence ALDD at the adjacent levels will be graded in accordance with the following definitions adapted from Kellgren and Lawrence: 0\. None: No degenerative changes. 1. Doubtful: Minimal osteophytosis only. 2. Minimal: Definite osteophytosis with some sclerosis of anterior part of vertebral plates. 3. Moderate: Marked osteophytosis and sclerosis of vertebral plates with slight narrowing of disk space. 4. Severe: Large osteophytes, marked sclerosis of vertebral plates, and marked narrowing of disk space. The assessment of Kellgren-Lawrence Osteoarthritis Grade will be graded by the reviewers based on an assessment from X-ray of three component factors: disc space narrowing (assessed relative to an nearby normal disc), osteophyte formation and endplate sclerosis.

    Time frame: Will be conducted before surgery (baseline), and 3 months, 6 months, and 1 year post-operation.

  10. Radiographic assessments: intervertebral angle (index and adjacent levels)

    Intervertebral Angle is used to define the endplate angle of the superior vertebra relative to the inferior vertebra. The difference in the angles measured is equivalent to a change in the Disc Angle. Intervertebral Angles will be measured in the sagittal plane from flexion and extension images separately and in the coronal plane from left and right bending images separately. All values will be reported in degrees. Intervertebral Angle will be calculated from lateral flexion-extension radiographs. Intervertebral Angle, also known as rotation, is defined as the change in angle between the adjacent endplates of the motion segment. Intervertebral Angle will be reported in units of degrees.

    Time frame: Will be conducted before surgery (baseline), and 3 months, 6 months, and 1 year post-operation.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Jul 2026, 38 months after the start.

Of 41 observational studies under Radiculopathy, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 95. This study's planned 38 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2022
First posted
Jan 27, 2023
StartActual
May 1, 2023
Primary completionEst.
Jul 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05701059
Responsible party
Daniel Lu, MD, PhD (Principal Investigator, Neuroplasticity and Repair Laboratory, University of California, Los Angeles) — Principal investigator
First posted
Jan 27, 2023
Start date
May 1, 2023
Primary completion
Jul 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Feb 13, 2026

Study contacts

Daniel C Lu, MD, PhD
Contact
dclu@mednet.ucla.edu
(310) 267-2975
Sandra Holley, PhD
Contact
sholley@mednet.ucla.edu
310-267-1770
Daniel C Lu, MD, PhD
principal investigator · University of California, Los Angeles

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion